Company Filing History:
Years Active: 2021-2024
Title: Mikhail Yudin: Innovator in Pharmaceutical Compounds
Introduction
Mikhail Yudin is a prominent inventor based in Moscow, Russia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific receptors related to metabolic disorders. With a total of 2 patents, Yudin's work is paving the way for new treatments in medicine.
Latest Patents
Yudin's latest patents focus on compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide, and benzo[d][1,3]oxathiole 3,3-dioxide. These compounds are designed as agonists of G protein-coupled receptor 119 (GPR119). The patents detail methods and uses related to these compounds, particularly in the treatment of diseases and conditions associated with GPR119 dysregulation, including Type 2 diabetes mellitus and related metabolic disorders.
Career Highlights
Mikhail Yudin is currently associated with Pramana Pharmaceuticals Inc., where he continues to innovate in the pharmaceutical sector. His work is characterized by a strong focus on developing effective treatments for metabolic disorders, showcasing his commitment to improving patient outcomes.
Collaborations
Yudin collaborates with notable colleagues such as Tarek Suhayl Mansour and Yury Gezentsvey. These partnerships enhance the research and development efforts at Pramana Pharmaceuticals Inc., fostering an environment of innovation and discovery.
Conclusion
Mikhail Yudin's contributions to pharmaceutical innovations are noteworthy, particularly in the realm of metabolic disorder treatments. His patents reflect a dedication to advancing medical science and improving health outcomes for patients worldwide.